Abeona Therapeutics Inc Expected to Earn Q1 2024 Earnings of ($0.47) Per Share (NASDAQ:ABEO)

Abeona Therapeutics Inc (NASDAQ:ABEO) – Investment analysts at Zacks Small Cap issued their Q1 2024 earnings per share estimates for Abeona Therapeutics in a research report issued on Thursday, April 25th. Zacks Small Cap analyst D. Bautz expects that the biopharmaceutical company will post earnings per share of ($0.47) for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($2.05) per share.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13).

A number of other research analysts have also commented on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $36.00 price target on shares of Abeona Therapeutics in a report on Tuesday, April 23rd. StockNews.com lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd.

Abeona Therapeutics Stock Performance

Shares of ABEO opened at $3.26 on Monday. The firm has a market capitalization of $89.16 million, a price-to-earnings ratio of -1.26 and a beta of 1.49. Abeona Therapeutics has a one year low of $2.83 and a one year high of $9.01. The stock’s fifty day moving average is $7.23 and its 200-day moving average is $5.62.

Insider Buying and Selling

In other news, SVP Brendan M. O’malley bought 8,600 shares of the stock in a transaction that occurred on Thursday, April 25th. The shares were purchased at an average cost of $3.24 per share, with a total value of $27,864.00. Following the completion of the acquisition, the senior vice president now directly owns 188,718 shares in the company, valued at $611,446.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.30% of the stock is owned by corporate insiders.

Institutional Trading of Abeona Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ABEO. Simplex Trading LLC raised its holdings in Abeona Therapeutics by 1,889.9% during the 3rd quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 13,418 shares during the period. Jump Financial LLC acquired a new stake in Abeona Therapeutics during the 4th quarter worth about $199,000. Schonfeld Strategic Advisors LLC acquired a new stake in Abeona Therapeutics during the 3rd quarter worth about $648,000. Worth Venture Partners LLC raised its holdings in Abeona Therapeutics by 76.6% during the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock worth $1,184,000 after buying an additional 121,969 shares during the period. Finally, Barclays PLC raised its holdings in Abeona Therapeutics by 100.0% during the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock worth $1,564,000 after buying an additional 185,638 shares during the period. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.